Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions.
暂无分享,去创建一个
L. Wienkers | L. Schaaf | J. Sams | L C Wienkers | P. Su | J G Slatter | L J Schaaf | J P Sams | P Su | J. Slatter | SU Ping | James P. Sams | Larry J. Schaaf
[1] H. Hakusui,et al. Pharmacokinetics of SN-38 [(+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H- pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-dione], an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats. , 1995, Biological & pharmaceutical bulletin.
[2] B. Hammock,et al. The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs. , 1996, Cancer research.
[3] N. Kemeny,et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Ratain,et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.
[5] A. Y. Lu,et al. Partial purification of cytochromes P-450 and P-448 from rat liver microsomes. , 1972, Biochemical and biophysical research communications.
[6] M. Ratain,et al. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital , 1997, Cancer Chemotherapy and Pharmacology.
[7] D. Petersen,et al. Purification and characterization of two rat liver microsomal carboxylesterases (hydrolase A and B). , 1994, Archives of biochemistry and biophysics.
[8] K. Thoma,et al. [Relationships between manufacturing parameters and pharmaceutical-technological requirements of biodegradable microparticles. 2. Preparation of injectable microparticles in biodegradable polyester]. , 1992, Die Pharmazie.
[9] N. Saijo,et al. Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. , 1994, Journal of the National Cancer Institute.
[10] T. Ohira,et al. Intracellular Carboxyl Esterase Activity Is a Determinant of Cellular Sensitivity to the Antineoplastic Agent KW‐2189 in Cell Lines Resistant to Cisplatin and CPT‐11 , 1995, Japanese journal of cancer research : Gann.
[11] Daniel M. Bender,et al. Quantitative kinetic assays for glutathione S-transferase and general esterase in individual mosquitoes using an EIA reader , 1989 .
[12] J. Robert,et al. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. , 1998, Cancer research.
[13] T. Burke,et al. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. , 1994, Journal of medicinal chemistry.
[14] T. J. Yang,et al. Differential sodium fluoride sensitivity of alpha-naphthyl acetate esterase in human, bovine, canine, and murine monocytes and lymphocytes. , 1991, Experimental hematology.
[15] J. Rask-Madsen,et al. Clinical Pharmacokinetics of Drugs Used in the Treatment of Gastrointestinal Diseases (Part I) , 1990, Clinical pharmacokinetics.
[16] T. Yoshimoto,et al. CPT-11 converting enzyme from rat serum: purification and some properties. , 1991, Journal of pharmacobio-dynamics.
[17] Jones Sf,et al. Topoisomerase I inhibitors: topotecan and irinotecan. , 1996, Cancer practice.
[18] J. Robert,et al. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. , 1996, Biochemical pharmacology.
[19] J. Suttie,et al. Fluoride inhibition of rat liver microsomal esterases. , 1974, The Journal of biological chemistry.
[20] S. Culine,et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] A. Tunek,et al. Bambuterol, a carbamate ester prodrug of terbutaline, as inhibitor of cholinesterases in human blood. , 1988, Drug metabolism and disposition: the biological fate of chemicals.
[22] Kensuke Matsumoto,et al. Production of SN-38, a Main Metabolite of the Camptothecin Derivative CPT-11, and Its Species and Tissue Specificities. , 1991 .
[23] E K Rowinsky,et al. The current status of camptothecin analogues as antitumor agents. , 1993, Journal of the National Cancer Institute.
[24] P. Hérait,et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. , 1994, Journal of the National Cancer Institute.
[25] J. Robert,et al. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes Differential hydrolysis for the lactone and carboxylate forms , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[26] T. Satoh,et al. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. , 1994, Biological & pharmaceutical bulletin.
[27] D. Kroetz,et al. Glycosylation-dependent activity of baculovirus-expressed human liver carboxylesterases: cDNA cloning and characterization of two highly similar enzyme forms. , 1993, Biochemistry.
[28] T. Satoh,et al. Interindividual variation in carboxylesterase levels in human liver microsomes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[29] S. Pond,et al. Purification and characterization of two human liver carboxylesterases. , 1989, The International journal of biochemistry.
[30] B. Yan,et al. Regulation of two rat liver microsomal carboxylesterase isozymes: species differences, tissue distribution, and the effects of age, sex, and xenobiotic treatment of rats. , 1994, Archives of biochemistry and biophysics.
[31] J. Verweij,et al. Topoisomerase I inhibitors: topotecan and irenotecan. , 1994, Cancer treatment reviews.
[32] R. Herrmann,et al. Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. , 1988, Cancer research.
[33] U. Kaveeshwar,et al. Difference in the inhibition of plasma carboxylesterase activity by metoclopramide in humans and laboratory animals. , 1992, Die Pharmazie.